Barclays PLC Increases Stake in Werewolf Therapeutics, Inc. (NASDAQ:HOWL)

Barclays PLC grew its stake in shares of Werewolf Therapeutics, Inc. (NASDAQ:HOWL) by 130.1% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 54,810 shares of the company’s stock after purchasing an additional 30,990 shares during the quarter. Barclays PLC owned approximately 0.12% of Werewolf Therapeutics worth $116,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Geode Capital Management LLC raised its holdings in Werewolf Therapeutics by 6.3% during the 3rd quarter. Geode Capital Management LLC now owns 685,989 shares of the company’s stock valued at $1,454,000 after buying an additional 40,692 shares during the last quarter. XTX Topco Ltd purchased a new position in shares of Werewolf Therapeutics in the third quarter valued at about $45,000. State Street Corp raised its stake in shares of Werewolf Therapeutics by 12.4% during the third quarter. State Street Corp now owns 476,439 shares of the company’s stock valued at $1,010,000 after acquiring an additional 52,528 shares during the last quarter. PFM Health Sciences LP boosted its holdings in shares of Werewolf Therapeutics by 4.9% during the third quarter. PFM Health Sciences LP now owns 3,398,747 shares of the company’s stock worth $7,205,000 after purchasing an additional 157,673 shares during the period. Finally, Walleye Capital LLC grew its stake in shares of Werewolf Therapeutics by 10.7% in the third quarter. Walleye Capital LLC now owns 108,968 shares of the company’s stock worth $231,000 after purchasing an additional 10,528 shares during the last quarter. Institutional investors own 64.84% of the company’s stock.

Werewolf Therapeutics Stock Performance

Shares of HOWL opened at $1.44 on Friday. Werewolf Therapeutics, Inc. has a one year low of $1.31 and a one year high of $8.19. The company has a 50-day simple moving average of $1.63 and a two-hundred day simple moving average of $2.07. The company has a debt-to-equity ratio of 0.29, a current ratio of 10.10 and a quick ratio of 10.10. The firm has a market capitalization of $64.17 million, a PE ratio of -0.94 and a beta of 0.38.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the company. HC Wainwright reaffirmed a “buy” rating and set a $15.00 price target on shares of Werewolf Therapeutics in a research report on Tuesday, November 19th. JMP Securities dropped their price target on Werewolf Therapeutics from $12.00 to $4.00 and set a “market outperform” rating for the company in a research note on Tuesday, January 14th.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.